Journal of Infection and Chemotherapy最新文献

{"title":"Active surveillance of vancomycin-resistant Enterococcus faecium after its outbreak at patient admission","authors":"Kento Furuya ,&nbsp;Kyohei Sugiyama ,&nbsp;Kiyomi Suzuki ,&nbsp;Masami Yamamoto ,&nbsp;Maiko Koyama ,&nbsp;Rie Sasaki ,&nbsp;Junko Kurioka ,&nbsp;Naoya Itoh","doi":"10.1016/j.jiac.2025.102718","DOIUrl":"10.1016/j.jiac.2025.102718","url":null,"abstract":"<div><div>Vancomycin-resistant <em>Enterococcus faecium</em> (VRE) causes high mortality and has been increasingly detected worldwide in recent years; however, its screening effectiveness at admission remains controversial. We aimed to evaluate the effectiveness of active surveillance culture (ASC) for VRE at admission following a nosocomial outbreak. A VRE outbreak occurred at Shizuoka General Hospital in 2022, and ASC for VRE was performed upon admission for high-risk cases after the outbreak between January 2023 and December 2023. ASC was conducted in 2941 patients at admission, with 13 of them testing positive (0.44 %). The highest cumulative incidence and odds ratios (ORs) of ASC positivity at admission were detected among patients with a VRE detection history (5/18, cumulative incidence: 27.78 %, OR: 140.14, <em>p</em> &lt; 0.001). The second highest cumulative incidence and OR occurred in patients hospitalized within the past 3 months in VRE-endemic areas (5/85, cumulative incidence: 5.88 %, OR: 22.25, <em>p</em> &lt; 0.001). Hospitalization at SGH within the past 3 months showed a low cumulative incidence and OR (1/2,034, cumulative incidence: 0.05 %, OR: 0.037, <em>p</em> = 0.002). Among patients with urinary catheters, three of 132 patients tested ASC-positive (cumulative incidence: 2.27 %, OR: 6.51, <em>p</em> = 0.05), and six out of 403 individuals requiring toilet assistance were ASC-positive (cumulative incidence: 1.49 %, OR: 5.46, <em>p</em> = 0.02). None of the ASC-positive patients had a history of nursing home admissions or diarrhea. Our findings suggest that following a VRE nosocomial outbreak, ASC at admission should be prioritized for patients with a history of VRE detection or recent hospitalization in VRE-endemic areas.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102718"},"PeriodicalIF":1.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of an intra-abdominal abscess caused by KPC-2-producing hypervirulent Klebsiella pneumoniae sequence type 11 with imipenem/cilastatin/relebactam in a Japanese patient","authors":"Kazuhiro Ishikawa ,&nbsp;Koko Shibutani ,&nbsp;Yumiko Mikami ,&nbsp;Sohei Harada ,&nbsp;Kohji Komori ,&nbsp;Nobuyoshi Mori","doi":"10.1016/j.jiac.2025.102717","DOIUrl":"10.1016/j.jiac.2025.102717","url":null,"abstract":"<div><div>KPC-producing <em>K. pneumoniae</em> is rare in Japan. In China, KPC-2-producing sequence type (ST)11 <em>K. pneumoniae</em> isolates have been rapidly increasing, and a subset of these isolates have acquired hypervirulence. We report a case of a 39-year-old Japanese male who developed bacteremia and intra-abdominal abscesses caused by hypervirulent carbapenem-resistant <em>K. pneumoniae</em>. The patient sustained abdominal injuries following a traffic accident in Xinjiang Uygur Autonomous Region and underwent abdominal surgery before being transferred to our hospital. Abscess drainage was performed, and he was initially treated with meropenem (2 g every 8 hours, prolonged infusion over 3 hours), gentamicin (5 mg/kg/day), and tigecycline (200 mg as a loading, followed by 100 mg every 12 hours). KPC carbapenemase was detected using the NG-Test® CARBA 5 (NG Biotech, France), and the minimum inhibitory concentration for imipenem/cilastatin/relebactam was 1 μg/mL, indicating susceptibility. His treatment was switched to imipenem/cilastatin/relebactam (1 g every 6 hours) for 7 weeks, resulting in clinical improvement. Whole-genome sequencing analysis revealed that the causative strain was hypervirulent KPC-2-producing <em>K. pneumoniae</em> (capsular type K64, ST 11) carrying <em>bla</em>_KPC-2 and <em>bla</em>_CTX-M-65 on a multireplicon plasmid (pMTY24772_IncFII-R), which was a fusion of IncFII and IncR. Additionally, <em>rmpA</em> and <em>iucABCD</em> genes associated with hypervirulence were detected. The strain carried a resistance plasmid and a virulence plasmid similar to those carried by ST11-K64 KPC-producing strains reported from China. Imipenem/cilastatin/relebactam is potentially an option for treating infections caused by KPC-2-producing hypervirulent <em>K, pneumoniae</em> with porin mutations. Cross-border spread of pathogens that are both multidrug-resistant and hyperviirulent must be closely monitored.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102717"},"PeriodicalIF":1.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial activity of tebipenem to Escherichia coli isolates from outpatients with complicated urinary tract infections","authors":"Masaya Ito ,&nbsp;Mitsuru Yasuda ,&nbsp;Masahiro Hayashi ,&nbsp;Kaori Tanaka","doi":"10.1016/j.jiac.2025.102712","DOIUrl":"10.1016/j.jiac.2025.102712","url":null,"abstract":"<div><div>Extended-spectrum β-lactamases (ESBL)-producing <em>Escherichia coli</em> have emerged as a global concern in urinary tract infections (UTIs). This study investigated the susceptibility of clinical isolates of <em>E. coli</em> from complicated UTIs (cUTIs) to tebipenem pivoxil (TBPM), an oral carbapenem developed in Japan. In 2019, 229 non-ESBL-producing and 61 ESBL-producing <em>E. coli</em> strains were collected from five major hospitals in the Gifu Prefecture. Susceptibility was assessed following the Clinical and Laboratory Standards Institute guidelines (M07 and M100), and TBPM was compared with other commonly used antibiotics. The MIC₅₀ and MIC₉₀ values of TBPM for non-ESBL and ESBL-producing <em>E. coli</em> were ≤0.03 μg/mL, with MIC ranges of ≤0.03–0.25 μg/mL and ≤0.03–0.06 μg/mL, respectively, indicating its strong antimicrobial activity. Notably, no strains demonstrated reduced susceptibility to TBPM. These results were comparable to those of intravenous carbapenems such as imipenem and meropenem. Additionally, these findings align with the national Japanese surveillance data, suggesting that the trends observed in this study may reflect broader patterns across Japan. In the United States, an ongoing study is evaluating TBPM hydrobromide for cUTIs, highlighting its potential as an effective oral carbapenem. TBPM may be a promising treatment option for cUTIs caused by ESBL-producing <em>E. coli</em>, offering an alternative to intravenous therapies and potentially reducing the need for hospitalization. However, careful use of TBPM in antimicrobial stewardship programs is crucial to prevent resistance and ensure its continued efficacy in outpatient settings.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102712"},"PeriodicalIF":1.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of antibiotic de-escalation based on the DASON criteria by pharmacist-led post-prescription review and feedback: A retrospective study in a medium-sized Japanese hospital","authors":"Atsuhiro Mizushima ,&nbsp;Satoru Mitsuboshi ,&nbsp;Seiya Kobayashi ,&nbsp;Kaori Hara ,&nbsp;Yoshiaki Ara ,&nbsp;Toshihiko Agatsuma","doi":"10.1016/j.jiac.2025.102716","DOIUrl":"10.1016/j.jiac.2025.102716","url":null,"abstract":"<div><h3>Introduction</h3><div>Among antimicrobial stewardship team (AST) activities, de-escalation, which is aimed at optimizing antibiotic use, lacks a standardized evaluation method. The Duke Antimicrobial Stewardship Outreach Network (DASON) criteria provide a framework for assessing de-escalation; however, their applicability in small to medium-sized hospitals in Japan has remained unclear. We aimed to evaluate the effectiveness of AST pharmacist-led post-prescription review and feedback (PPRF) using multiple indicators, including de-escalation based on the DASON criteria, to determine whether these indicators are also applicable in medium-sized hospitals.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted at a 330-bed hospital, comparing pre-PPRF (April 2021 to March 2022) and post-PPRF (April 2022 to March 2023) periods. The effectiveness of AST pharmacist-led PPRF was evaluated using the de-escalation rate determined by the DASON criteria, inappropriate antibiotic use in definitive therapy, days of therapy (DOT), and days of antibiotic spectrum coverage (DASC) per DOT.</div></div><div><h3>Results</h3><div>The de-escalation rate significantly increased from 20 % to 45 % (<em>P</em> &lt; 0.01), and inappropriate antibiotic use in definitive therapy decreased from 7 % to 0 % after AST pharmacist-led PPRF. While DOT significantly increased from 11 days to 13 days (<em>P</em> = 0.02), no significant change was observed in the DASC/DOT ratio.</div></div><div><h3>Conclusion</h3><div>This study suggests that de-escalation based on the DASON criteria can be an effective quantitative indicator for evaluating AST pharmacist-led PPRF in medium-sized hospitals. The findings also suggest that incorporating multiple indicators tailored to each hospital's conditions can provide a more comprehensive framework for evaluating AST pharmacist-led PPRF.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102716"},"PeriodicalIF":1.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-vaccinal seronegative autoimmune encephalitis following recombinant zoster vaccination in two immunocompetent patients","authors":"Tariq A. Madani ,&nbsp;Abeer A. Khoja ,&nbsp;Ahmad R. Abuzinadah ,&nbsp;Ghada M. Abbas ,&nbsp;Alaa A. Alotaibi ,&nbsp;Ziad I. Alshehri ,&nbsp;Salman T. Madani","doi":"10.1016/j.jiac.2025.102713","DOIUrl":"10.1016/j.jiac.2025.102713","url":null,"abstract":"<div><h3>Background</h3><div>Varicella Zoster Virus (VZV) causes varicella as a primary infection and establishes latency in sensory ganglia. Reactivation in adults leads to herpes zoster (HZ). A highly effective recombinant zoster vaccine (Shingrix®) was recently developed to prevent HZ. While vaccine safety data is reassuring, we report two cases of post-vaccinal seronegative autoimmune encephalitis (AE) following the first dose of the Shingrix® vaccine.</div></div><div><h3>Case 1</h3><div>A 67-year-old male surgeon presented one week after receiving the vaccine with a one-day history of dizziness, fatigue, and insomnia, followed the next day by confusion, agitation, terrifying visual hallucinations, paraphasic errors, and echolalia. Brain imaging and cerebrospinal fluid (CSF) analysis were unremarkable. The CSF multiplex polymerase chain reaction (PCR) panel targeting 14 bacterial and viral pathogens associated with meningitis/encephalitis was negative. All known AE antibodies were also negative. The patient initially improved with empiric anti-meningitis/encephalitis therapy, including a two-day course of steroids but he relapsed shortly after stopping the steroids, necessitating re-admission. Pulse steroid therapy followed by plasmapheresis led to full recovery.</div></div><div><h3>Case 2</h3><div>A 50-year-old female pediatrician presented with acute confusion nine days after the Shingrix® vaccination. CSF analysis showed lymphocytic-predominant mild pleocytosis and elevated protein, but brain imaging was unremarkable. The CSF meningitis/encephalitis PCR panel and AE antibodies were negative. Pulse steroid therapy and plasmapheresis led to full recovery.</div></div><div><h3>Conclusions</h3><div>These two cases highlight the potential for AE following the administration of the Shingrix® vaccine and underscore the importance of prompt recognition and aggressive immunotherapy to prevent morbidity and mortality.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102713"},"PeriodicalIF":1.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment satisfaction and needs among people living with HIV who have incomplete viral load suppression in Japan: A multicenter, cross-sectional, observational study","authors":"Takeshi Kimura ,&nbsp;Shinichi Hikasa ,&nbsp;Masashi Ishihara ,&nbsp;Mariko Tsukiji ,&nbsp;Yusuke Kunimoto ,&nbsp;Kazuko Nobori ,&nbsp;Kenta Onishi ,&nbsp;Yuuki Yamamoto ,&nbsp;Kyohei Haruta ,&nbsp;Yohei Kashiwabara ,&nbsp;Kenji Fujii ,&nbsp;Kazuhiro Yamamoto ,&nbsp;Tomohiro Omura ,&nbsp;Kei Ebisawa ,&nbsp;Goh Ohji ,&nbsp;Kentaro Iwata ,&nbsp;Ikuko Yano","doi":"10.1016/j.jiac.2025.102711","DOIUrl":"10.1016/j.jiac.2025.102711","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the association between viral-load (VL)-suppression status and treatment satisfaction, depression, anxiety, and treatment needs in people living with HIV (PLWH).</div></div><div><h3>Methods</h3><div>A multicenter, cross-sectional study was conducted from April to December 2021. Eligible patients were classified into two groups based on their VL in the year prior to answering the questionnaires: those with all VL &lt; 50 copies/mL (complete-VL-suppression group) and those with at least one VL ≥ 50 copies/mL (incomplete-VL-suppression group). The HIV Treatment Satisfaction Questionnaire: Status (HIVTSQs), the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7), and the drug formulation needs were compared between the two groups.</div></div><div><h3>Results</h3><div>Of the 534 patients included in the analysis, 467 and 67 were classified into the complete and incomplete-VL-suppression groups, respectively. The total HIVTSQs scores (median [interquartile range (IQR)]) were 59.0 [53.0–64.0] and 56.0 [52.0–62.5] in the complete and incomplete-VL-suppression groups, respectively, with no significant difference. The incomplete-VL-suppression group scored significantly lower on the individual question for HIV control than the complete-VL-suppression group (5.0 [5.0–6.0] vs. 6.0 [5.0–6.0], <em>P</em> = 0.001). The total PHQ-9 and GAD-7 scores were not significantly different between the groups. The proportion of patients who preferred the once-every-month subcutaneous formulation was higher in the incomplete-VL-suppression group compared to the complete-VL-suppression group (16.4 % vs. 7.5 %, <em>P</em> = 0.028).</div></div><div><h3>Conclusions</h3><div>The association between VL-suppression status and overall treatment satisfaction, depression, or anxiety was not detected. However, satisfaction with HIV control and treatment needs may differ in PLWH with incomplete VL-suppression.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102711"},"PeriodicalIF":1.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended-pulsed fidaxomicin therapy for recurrent Clostridioides difficile infection after standard vancomycin and fidaxomicin failure: A case report","authors":"Jun Hirai","doi":"10.1016/j.jiac.2025.102709","DOIUrl":"10.1016/j.jiac.2025.102709","url":null,"abstract":"<div><div><em>Clostridioides difficile</em> infection (CDI) is a leading cause of healthcare-associated diarrhea. Recurrence occurs in up to 60 % of patients following multiple episodes, posing a major clinical challenge. While vancomycin (VCM) and fidaxomicin (FDX) are recommended first-line therapies, treatment failures and recurrences are not uncommon. Extended-pulsed fidaxomicin (EPFX) has been proposed to reduce recurrence, especially in high-risk patients, though the evidence remains limited for those with multiple prior relapses. We report the case of a 66-year-old man with advanced esophageal and gastric cancer who experienced four episodes of recurrent CDI despite standard treatment with VCM and FDX. Given the unavailability of bezlotoxumab (BEZ) in Japan and the limited accessibility of fecal microbiota transplantation (FMT), EPFX was selected as a salvage regimen. After both EPFX and pulse-tapered oral VCM were explained, the patient and physician elected to initiate EPFX, consisting of 200 mg twice daily for five days followed by 200 mg every other day for 20 days. No further recurrences were observed for over four months, and no adverse effects were noted. This case supports the use of EPFX in patients with multiple high-risk features—including advanced age, active malignancy, and prior treatment failures—despite the EXTEND trial's exclusion of patients with ≥3 recurrences. The favorable pharmacokinetic properties of FDX may have contributed to its efficacy. Importantly, the patient's medication, nutritional, and oncologic status remained stable throughout treatment, suggesting that EPFX played a pivotal role in achieving remission. EPFX may offer a viable option for patients with recurrent CDI refractory to standard therapies.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102709"},"PeriodicalIF":1.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A multicenter prospective observational study on mechanically ventilated ICU patients in the COVID-19 recovery study II","authors":"Junji Hatakeyama ,&nbsp;Kensuke Nakamura ,&nbsp;Naoki Kanda ,&nbsp;Akira Kawauchi ,&nbsp;Shigeki Fujitani ,&nbsp;Taku Oshima ,&nbsp;Hideaki Kato ,&nbsp;Kohei Ota ,&nbsp;Hiroshi Kamijo ,&nbsp;Tomohiro Asahi ,&nbsp;Yoko Muto ,&nbsp;Miyuki Hori ,&nbsp;Arisa Iba ,&nbsp;Mariko Hosozawa ,&nbsp;Hiroyasu Iso","doi":"10.1016/j.jiac.2025.102708","DOIUrl":"10.1016/j.jiac.2025.102708","url":null,"abstract":"<div><h3>Background</h3><div>Tocilizumab, an IL-6 receptor antagonist, may prevent functional impairments in critically ill patients by attenuating the cytokine storm. This study investigated a potential effect of tocilizumab on preventing functional impairments in patients with severe coronavirus infection 2019 (COVID-19).</div></div><div><h3>Methods</h3><div>In a multicenter prospective observational study, patients with COVID-19 ≥ 20 years requiring mechanical ventilation admitted to the intensive care unit between April 2021 and September 2021 and discharged alive were followed for one year. A self-administered questionnaire on sequelae and functional impairments was mailed in August 2022, and data were collected. A multivariate logistic regression was used to assess the impact of tocilizumab on physical function, mental health, and Long COVID.</div></div><div><h3>Results</h3><div>Of 157 analyzed patients, 41 received tocilizumab. The tocilizumab group had more severe illness, but a lower prevalence of physical impairment (17.1 % vs. 23.3 %, p = 0.41) and mental disorders (19.5 % vs. 39.7 %, p = 0.009) than the non-tocilizumab group. The prevalence of Long COVID was higher in the tocilizumab group (92.7 % vs. 80.2 %, p = 0.06), whereas fatigue/malaise was significantly lower (19.5 % vs. 37.1 %, p = 0.039). Adjusted odds ratios (95 % confidence interval) for physical impairment, mental disorders, and Long COVID with tocilizumab were 0.70 (0.2–2.1), 0.40 (0.16–1.01), and 2.94 (0.7–12.3), respectively, with no significant difference.</div></div><div><h3>Conclusions</h3><div>Tocilizumab was associated with a lower prevalence of physical impairment and mental disorders at 1 year in patients with severe COVID-19. Furthermore, Long COVID had a weaker impact on physical and cognitive functions.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102708"},"PeriodicalIF":1.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Impact of BD BACTEC blood culture bottle shortage on performance metrics: An interrupted time-series analysis at a Japanese university-affiliated hospital” [J Infect Chemother (2025) 31(4) 102664]","authors":"N. Itoh,&nbsp;N. Akazawa-Kai,&nbsp;N. Okumura,&nbsp;S. Kuriki,&nbsp;C. Wachino,&nbsp;T. Kawabata","doi":"10.1016/j.jiac.2025.102710","DOIUrl":"10.1016/j.jiac.2025.102710","url":null,"abstract":"","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102710"},"PeriodicalIF":1.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of Japanese encephalitis in a previously non-reported area: Three consecutive annual cases from a tertiary center in Narita, Chiba, Japan","authors":"Koki Yoshizawa ,&nbsp;Emiri Muranaka ,&nbsp;Ryota Hase ,&nbsp;Masahiro Namiki ,&nbsp;Satoki Hanayama ,&nbsp;Yukiko Ozawa ,&nbsp;Shogo Furukawa ,&nbsp;Yuriko Kikkawa","doi":"10.1016/j.jiac.2025.102706","DOIUrl":"10.1016/j.jiac.2025.102706","url":null,"abstract":"<div><div>The number of Japanese encephalitis (JE) cases dramatically decreased after implementing national vaccination program in Japan and the diagnosis requires specific tests in the reference laboratory in most cases. We report three consecutive cases of JE in a single hospital in Narita over three years. Although the PCR test confirmed the diagnosis in one case, the PCR was negative and IgM captured ELISA in the reference laboratory confirmed the diagnosis in the other two cases. These cases suggest that the number of JE patients may be underestimated in Japan. Physicians should consider JE as a differential diagnosis, when encountering the cases of encephalitis or meningitis with unknown etiology during the warm season even in the area where JE has not been reported.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102706"},"PeriodicalIF":1.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}